Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)

Portola Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Thromboembolism

Treatments: Drug: Betrixaban; Drug: Enoxaparin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00375609

PRT05-003

Details and patient eligibility

About

Randomized study of PRT054021 40 mg and 15 mg bid vs. enoxaparin 30 mg q12h for the prophylaxis of venous thromboembolic events after unilateral knee replacement surgery.

Full description

Approximately 200 patients undergoing unilateral knee replacement will be entered into the study and randomized to receive either enoxaparin 30 mg sq bid, PRT054021 15 mg po bid, or PRT054021 40 mg po bid for 10 to 14 days, at which time patients will undergo venography.

Enrollment: 215 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• • The subject has undergone elective primary unilateral TKR (not unicompartmental).

Demographic

• The subject is between the ages of 18 and 75 years.
• If the subject is a woman, she is without reproductive potential (postmenopausal for >2 years or after hysterectomy).
• The subject weighs between 50 kg (110 lbs) and 120 kg (265 lbs). Laboratory and Procedures
• The subject is willing and able to undergo unilateral venography. Medications
• The subject is willing and able to self-inject enoxaparin or receive injections q12h by a caregiver.

Ethical • The subject is able to read and give written informed consent and has signed an informed consent form approved by the Investigator's IRB/IEC.

Exclusion criteria

• Disease Related

  • Major medical and/or surgical condition which may impair oral drug absorption or metabolism.
  • Immobilization for 3 or more days before surgery.
  • History (including family history) or symptoms of a congenital or acquired bleeding disorder or vascular malformation; or a history of intracranial, retroperitoneal, or intraocular bleeding within the last 6 months; or is felt to be at high risk for bleeding for other reasons.
  • Gastrointestinal bleeding within 90 days before surgery or endoscopically verified ulcer disease within 30 days before surgery.
  • Indwelling intrathecal or epidural catheter during the prophylaxis period (except for epidural catheter if removed after surgery); or unusual difficulty in administering spinal or epidural anesthesia (eg, 3 or more attempts, "traumatic taps").
  • Major surgery, ischemic stroke, or myocardial infarction within 3 months before Screening.
  • Uncontrolled hypertension defined as systolic blood pressure (SBP) > 180 mmHg or diastolic blood pressure (DBP) >105 mmHg.
  • Hypotension defined as SBP <95 mmHg.
  • Evidence at Screening of symptomatic congestive heart failure requiring treatment.
  • Chronic atrial fibrillation treated with oral anticoagulants, recurrent atrial arrhythmia(s) or a history of recurrent ventricular tachycardia.

Laboratory and Procedures

• Evidence at Screening of: platelet count <100,000/mm3 potassium <3.5 mEq/L hemoglobin concentration <10 g/dL or hematocrit <30% serum ALT or AST >2 times ULN serum creatinine >2.0 mg/dL (180 µm/L)

• Contraindication to venography, including to iodinated contrast medium
• QTc on Screening ECG >450 msec and/or a personal or family history of "Long QT Syndrome".

Medications

• Contraindication to anticoagulation for VTE prophylaxis, including a contraindication to receiving heparin or heparinoids.
• Administration of the following drugs within 7 days before TKR: thrombolytic agents, anticoagulants and/or anti-platelet agents (eg, heparins, warfarin, dipyridamole, sulfinpyrazone, ticlopidine, dextran, clopidogrel). Aspirin up to 325 mg once daily and NSAIDs are allowed but discouraged.
• Use of class III antiarrhythmics drugs (eg, dofetilide, ibutilide, amiodarone, bretylium, sotalol) within 30 days prior to TKR.

General

• Participation in any investigational drug study 30 days prior to enrollment is prohibited. Participation in a device trial prior to enrollment is acceptable.
• Any condition which could interfere with or for which the treatment of might interfere with the conduct of the study, or which would, in the opinion of the Investigator, unacceptably increase the risk of the subject's participation in the study. This would include, but is not limited to alcoholism, drug dependency or abuse, psychiatric disease, epilepsy or any unexplained blackouts.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

215 participants in 3 patient groups

Betrixaban 15 mg

Experimental group

Description:

Betrixaban 15 mg oral twice daily for 10 to 14 days

Treatment:

Drug: Betrixaban

Betrixaban 40 mg

Experimental group

Description:

Betrixaban 40 mg oral twice daily for 10 to 14 days

Treatment:

Drug: Betrixaban

Enoxaparin

Experimental group

Description:

Enoxaparin 30 mg administered subcutaneously every 12 hours for 10 to 14 days

Treatment:

Drug: Enoxaparin